NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$217.10
-4.34 (-1.96 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$217.00
$222.24
50-Day Range
$180.55
$233.54
52-Week Range
$129.21
$235.85
Volume2.41 million shs
Average Volume3.93 million shs
Market Capitalization$208.20 billion
P/E Ratio32.45
Dividend Yield1.54%
Beta0.24
30 days | 90 days | 365 days | Advanced Chart
Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.


Eli Lilly and logo

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

51st out of 2,105 stocks

Pharmaceutical Preparations Industry

24th out of 832 stocks

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Eli Lilly and (NYSE:LLY) Frequently Asked Questions

Is Eli Lilly and a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and
or view top-rated stocks.

What stocks does MarketBeat like better than Eli Lilly and?

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Eli Lilly and
.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Monday, April, 26th. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $2.12 by $0.25. The firm had revenue of $6.81 billion for the quarter, compared to analysts' expectations of $7.10 billion. Eli Lilly and had a net margin of 23.91% and a trailing twelve-month return on equity of 132.28%. The business's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.75 earnings per share.
View Eli Lilly and's earnings history
.

How has Eli Lilly and's stock been impacted by Coronavirus (COVID-19)?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LLY shares have increased by 55.0% and is now trading at $217.10.
View which stocks have been most impacted by COVID-19
.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, May 3rd. Investors of record on Friday, May 14th will be paid a dividend of $0.85 per share on Thursday, June 10th. This represents a $3.40 dividend on an annualized basis and a yield of 1.57%. The ex-dividend date of this dividend is Thursday, May 13th.
View Eli Lilly and's dividend history
.

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.54%. Eli Lilly and does not yet have a strong track record of dividend growth. The dividend payout ratio of Eli Lilly and is 42.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.14% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and declared that its board has approved a share repurchase program on Monday, May 3rd 2021, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its shares are undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 7.800-8.000 for the period, compared to the Thomson Reuters consensus estimate of $8.230. The company issued revenue guidance of $26.60 billion-$27.60 billion, compared to the consensus revenue estimate of $27.69 billion.

What price target have analysts set for LLY?

13 equities research analysts have issued 12 month target prices for Eli Lilly and's shares. Their forecasts range from $144.00 to $270.00. On average, they anticipate Eli Lilly and's share price to reach $214.00 in the next year. This suggests that the stock has a possible downside of 1.4%.
View analysts' price targets for Eli Lilly and
or view top-rated stocks among Wall Street analysts.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 53, Pay $4.24M)
  • Dr. Daniel M. Skovronsky, Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs (Age 47, Pay $2.14M)
  • Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 52, Pay $1.72M)
  • Mr. Alfonso G. Zulueta, Sr. VP & Pres of Lilly International (Age 58, Pay $1.85M)
  • Mr. Joshua L. Smiley, Exec. Officer (Age 51, Pay $1.04M)
  • Ms. Anat Ashkenazi, Sr. VP & CFO (Age 48)
  • Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin. (LinkedIn Profile)
  • Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 58)
  • Mr. Diogo Rau, Sr. VP & Chief Information and Digital Officer
  • Kevin Hern, VP of Investor Relations

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Who are some of Eli Lilly and's key competitors?

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a number of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (11.50%), BlackRock Inc. (6.16%), The PNC Financial Services Group Inc. (5.44%), Primecap Management Co. CA (3.69%), Price T Rowe Associates Inc. MD (2.73%) and Geode Capital Management LLC (1.40%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Donald A Zakrowski, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and
.

Which major investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Franklin Resources Inc., Primecap Management Co. CA, Janus Henderson Group PLC, Lilly Endowment Inc., Massachusetts Financial Services Co. MA, Robeco Institutional Asset Management B.V., and Bank of Montreal Can. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Donald A Zakrowski, Lilly Endowment Inc, and Melissa S Barnes.
View insider buying and selling activity for Eli Lilly and
or view top insider-selling stocks.

Which major investors are buying Eli Lilly and stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Jennison Associates LLC, Ameriprise Financial Inc., Oak Ridge Investments LLC, Rockefeller Capital Management L.P., Bank of New York Mellon Corp, Fisher Asset Management LLC, and Bridge Creek Capital Management LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and
or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $217.10.

How much money does Eli Lilly and make?

Eli Lilly and has a market capitalization of $208.20 billion and generates $24.54 billion in revenue each year. The company earns $6.19 billion in net income (profit) each year or $7.93 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

Where are Eli Lilly and's headquarters?

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.